The 22nd International AIDS Conference (AIDS 2018) is being held in Amsterdam, the Netherlands, from 23 to 27 July 2018.
HIV i-Base reports:
- Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study
- No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)
- Using PrEP with feminising hormone therapy support daily PrEP dosing for transwomen
- Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil
- DTG/3TC dual therapy significantly worse with low CD4 counts – GEMINI study abstract reported non-inferiority but missed important details
- First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough
- Zero HIV transmissions in PARTNER study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV
- Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians
- Caution on press conference news at AIDS 2018
- i-Base Fit for Purpose report launched at AIDS 2018
- 10th International Workshop on HIV Paediatrics (Pre-conference workshop)
- Preconception safety signal with dolutegravir: data from the Tsepamo study
- 22nd International AIDS Conference (AIDS 2018) – Intorduction
- AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference
